Morphea secondary to interferon beta1b injection : a case and review of the literature
Interferon beta (IFNβ) is a drug used successfully in the treatment of multiple sclerosis (MS). Although IFNβ is a safe and well-tolerated drug, dermatological side effects are common. The most common dermatological adverse effect is a local reaction at the injection site. It may also cause inflammatory and immune-mediated dermatological side effects. However, morphea induced by IFNβ1b injection is very rare.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Dermatology online journal - 25(2019), 4 vom: 15. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ozlu, Emin [VerfasserIn] |
|---|
| Themen: |
145155-23-3 |
|---|
| Anmerkungen: |
Date Completed 06.12.2019 Date Revised 17.12.2019 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM29666524X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29666524X | ||
| 003 | DE-627 | ||
| 005 | 20231225090328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0988.xml |
| 035 | |a (DE-627)NLM29666524X | ||
| 035 | |a (NLM)31046913 | ||
| 035 | |a (PII)13030/qt41v3p52s | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ozlu, Emin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Morphea secondary to interferon beta1b injection |b a case and review of the literature |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2019 | ||
| 500 | |a Date Revised 17.12.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Interferon beta (IFNβ) is a drug used successfully in the treatment of multiple sclerosis (MS). Although IFNβ is a safe and well-tolerated drug, dermatological side effects are common. The most common dermatological adverse effect is a local reaction at the injection site. It may also cause inflammatory and immune-mediated dermatological side effects. However, morphea induced by IFNβ1b injection is very rare | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Interferon beta-1b |2 NLM | |
| 650 | 7 | |a 145155-23-3 |2 NLM | |
| 700 | 1 | |a Karadag, Ayse Serap |e verfasserin |4 aut | |
| 700 | 1 | |a Akdeniz, Necmettin |e verfasserin |4 aut | |
| 700 | 1 | |a Uzuncakmak, Tugba Kevser |e verfasserin |4 aut | |
| 700 | 1 | |a Zemheri, Ebru |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkanli, Seyma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatology online journal |d 1997 |g 25(2019), 4 vom: 15. Apr. |w (DE-627)NLM090971183 |x 1087-2108 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:4 |g day:15 |g month:04 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2019 |e 4 |b 15 |c 04 | ||